• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Synthesizing a deadly mushroom toxin

Bioengineer by Bioengineer
April 11, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The death-cap mushroom has a long history as a tool of murder and suicide, going back to ancient Roman times. The fungus, Amanita phalloides, produces one of the world's deadliest toxins: α-amanitin. While it may seem ill-advised, researchers are eager to synthesize the toxin because studies have shown that it could help fight cancer. Scientists now report in the Journal of the American Chemical Society how they overcame obstacles to synthesize the death-cap killer compound.

α-Amanitin achieves its impressive deadliness by acting as a potent inhibitor of RNA polymerase II, the enzyme primarily responsible for transcribing genes into the messenger molecule RNA. Using α-amanitin bound to antibodies against tumor molecules, cancer researchers have reportedly cured mice of pancreatic cancer. These conjugates are currently in human trials; however, the only way to obtain α-amanitin so far has been to harvest mushrooms, which is time-consuming and results in relatively small amounts of the compound. Synthetic production approaches have been hampered by α-amanitin's unusual bicyclic structure, among other tricky features. David M. Perrin and colleagues decided to take on the challenge to produce the toxin in the laboratory, once and for all.

The researchers had to work through three key obstacles to produce α-amanitin in the laboratory: production of the "oxidatively delicate" 6-hydroxy-tryptathionine, the an enantio- selective synthesis of (2S,3R,4R)-4,5-dihydroxy-isoleucine and a diastereoselective sulfoxidation to favor the (R)-sulfoxide. Due to its toxic nature, the researchers limited production to less than a milligram, but based on their results, they are confident that good yields are can be readily obtained by scaling up the process. The researchers also say that the development of this synthetic route will enable chemists to attenuate the toxicity and potentially improve α-amanitin's activity against cancer, something that is only made possible by the use of synthetic derivatives.

###

The authors acknowledge funding from the Natural Sciences and Engineering Research Council of Canada, the Canadian Institutes of Health Research and the Canadian Cancer Society.

The abstract that accompanies this study is available here.

The American Chemical Society, the world's largest scientific society, is a not-for-profit organization chartered by the U.S. Congress. ACS is a global leader in providing access to chemistry-related information and research through its multiple databases, peer-reviewed journals and scientific conferences. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact [email protected].

Follow us on Twitter | Facebook

Media Contact

Katie Cottingham
[email protected]
301-775-8455
@ACSpressroom

http://www.acs.org

Share12Tweet7Share2ShareShareShare1

Related Posts

Digital Health Perspectives from Baltic Sea Experts

February 7, 2026

Exploring Decision-Making in Dementia Caregivers’ Mobility

February 7, 2026

Succinate Receptor 1 Limits Blood Cell Formation, Leukemia

February 7, 2026

Palmitoylation of Tfr1 Drives Platelet Ferroptosis and Exacerbates Liver Damage in Heat Stroke

February 7, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Digital Health Perspectives from Baltic Sea Experts

Florida Cane Toad: Complex Spread and Selective Evolution

Exploring Decision-Making in Dementia Caregivers’ Mobility

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.